Make the answer shorter: World’s first contraceptive app, Natural Cycles, raises $55M

Natural Cycles' achievement is remarkable, marking a pivotal moment in the landscape of women's health technology. Founded in 2013 by Dr. Elina Berglund Scherwitzl and Dr. Raoul Scherwitzl, the company has spearheaded a revolution in contraceptive methods with the development of the world's first direct-to-consumer birth control app.

With over three million users globally, Natural Cycles has not only demonstrated its effectiveness but has also earned the trust of regulators across multiple jurisdictions. Being cleared by esteemed regulatory bodies such as the FDA in the United States, TÜV SÜD in Europe, Health Canada, TGA in Australia, HSA in Singapore, and MFDS in South Korea, underscores the app's reliability and safety.

This recent $55 million Series C financing round, bringing the total funding to over $95 million, is a testament to the growing recognition and support for Natural Cycles' mission to empower individuals with accessible, reliable, and personalized contraceptive options. As they continue to innovate and expand their reach, Natural Cycles is poised to further revolutionize the field of women's health and contraception.

The introduction of NC° Postpartum within the Natural Cycles app represents a significant step forward in supporting new mothers during the delicate postpartum period. This addition, alongside the existing modes for birth control, planning pregnancy, and follow-up during pregnancy, demonstrates Natural Cycles' commitment to providing comprehensive support throughout every stage of the fertility journey.

The recent funding led by Lauxera Capital Partners, with participation from Point72 Private Investments and backing from J.P. Morgan, underscores the confidence in Natural Cycles' innovative approach and its potential to shape the future of women's health technology. Samuel Levy's statement highlights the recognition of Natural Cycles' unique clinical and regulatory achievements, positioning the company as a leader in leveraging technology to empower individuals in managing their reproductive health effectively.

Samuel Levy's inclusion on Natural Cycles' Board of Directors signals a strategic partnership aimed at driving the company's growth and innovation forward. With the newly secured funds earmarked for commercial expansion, product innovation, and streamlining healthcare reimbursement processes, Natural Cycles is poised to further enhance its offerings and accessibility.

The leadership of Dr. Elina Berglund Scherwitzl and Dr. Raoul Scherwitzl, coupled with this infusion of capital and expertise, positions Natural Cycles to continue revolutionizing women's health technology and making meaningful strides in reproductive healthcare worldwide.